The Medical Readiness Contracting Office West (MRCO -W) is issuing Solicitation Amendment 0002 for a cost-per-reportable-result agreement to conduct hematology testing for the CBC, Reticulocyte counts, and Body Fluid Count in support of the BAMC.

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

W40M MRC0 WEST

Contract Value

Not provided

Codes & Classification
Solicitation Number

W81K00-26-Q-A080

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

6640

Additional Details
Set Aside

NONE

Place of Performance

JBSA Ft Sam Houston, Texas, UNITED STATES

SourceSAM
Documents2
The Medical Readiness Contracting Office West (MRCO-W), operating under the Department of the Army, has issued Solicitation Amendment 0002 for procurement identifier W81K00-26-Q-A080. This solicitation seeks to establish a cost-per-reportable-result agreement for the provision of hematology testing services, specifically encompassing Complete Blood Count (CBC), Reticulocyte counts, and Body Fluid Count analyses. The services are intended to support the Brooke Army Medical Center (BAMC) located at Joint Base San Antonio (JBSA) Ft Sam Houston, Texas. The primary objective of this procurement is to ensure reliable, high-quality hematology testing that meets the clinical and operational needs of BAMC. The scope of work includes the provision of all necessary in-vitro diagnostic substances, equipment, and associated services required to deliver accurate and timely reportable results for the specified hematology tests. The anticipated outcome is to enhance the medical readiness and diagnostic capabilities of BAMC by ensuring consistent access to essential laboratory testing. Amendment 0002 to the solicitation serves several key purposes: it provides official responses to offeror questions submitted in response to the original solicitation issued on April 1, 2026; it incorporates a revised Statement of Objectives dated April 10, 2026, which further clarifies the requirements for hematology testing; and it confirms that the proposal submission deadline remains unchanged—Monday, April 27, 2026, at 1:00 PM CST. All other terms and conditions of the solicitation remain in effect. This procurement is classified under NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing, 2022 version) and Product Service Code 6640. There are no set-aside restrictions associated with this opportunity, making it open to all qualified vendors. The place of performance is specified as JBSA Ft Sam Houston, Texas. The contracting entity for this requirement is W40M MRCO WEST, a federal office within the Department of Defense, Department of the Army. Interested parties may direct inquiries to the primary point of contact, Medina L. Woodson ([email protected], 210-808-5753), or the secondary contact, Salameya Paulouskaya ([email protected], 210-539-8656). Both contacts can also be reached via fax at 210-221-3446. Contractors considering this opportunity should review the revised Statement of Objectives and the official responses to offeror questions to ensure alignment with the technical and operational requirements. The solicitation remains active, and all relevant documents and attachments are accessible via the official SAM.gov opportunity posting (Opportunity ID: 9f36e828b7cb40839d4d071b7250a646). This procurement represents a critical support function for BAMC, with an emphasis on quality, reliability, and compliance with federal standards for in-vitro diagnostic services. Contractors with demonstrated expertise in hematology testing and the capacity to deliver consistent, reportable results are encouraged to respond by the stated deadline.